Samsung Bioepis' etanercept biosimilar, Brenzys receives Canadian approval to treat RA & ankylosing spondylitis

Wednesday, September 14, 2016, 16:00 Hrs  [IST] Samsung Bioepis Co., Ltd. announced that Brenzys – a biosimilar referencing Enbrel (etanercept), also known as SB4 – received regulatory approval in Canada for the treatment of rheumatoid arthritis and ankylosing spondylitis. Brenzys will be commercialized in Canada by Merck Canada Inc. “As evidenced in other markets, we believe Brenzys will help drive down healthcare costs and increase patient access to one of the most widely used autoimmune treatment options in Canada,” said Christopher Hansung Ko, president & CEO of Samsung Bioepis. “We remain committed to advancing one of the industry's largest biosimilar pipelines, so that more patients across Canada can access affordable, high-quality treatment.” Prior to receiving approval in Canada, Samsung Bioepis’ SB4 etanercept biosimilar received regulatory approvals from Korea’s Ministry of Food and Drug Safety (MFDS) as Brenzys in September 2015, the European Commission (EC) as Benepali in January 2016 and Australia’s Therapeutic Goods Administration (TGA) as Brenzys in July 2016. Samsung Bioepis is responsible for the development and manufacture of all immunology and oncology biosimilar candidates in its pipeline, including Brenzys, as well as global clinical trials and regulatory registration in all markets worldwide for these biosimilar candidates. Following approval, Samsung Bioepis biosimilar products are marketed and distributed by its commercialization partners, Biogen and Merck, which is known as MSD outside the United States and Canada. The regulatory submission for Brenzys was based on data from a randomized, double-blind 52-week phase III study, involving 596 patients with moderate to severe rheumatoid arthritis across 70 sites in 10 countries, who were treated with either weekly dose of subcutaneous 50 mg SB4 or Enbrel with background methotrexate. At week 52, SB4 showed ACR20 response rate of 80.8% in the SB4 arm versus 81.5% in the Enbrel arm, fully supporting the 24-week study results of 78.1% and 80.3%, respectively. Samsung Bioepis continues to advance a broad pipeline of 13 biosimilar candidates, which includes the following six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes: SB4 biosimilar candidate referencing Enbrel (etanercept); SB2 biosimilar candidate referencing Remicade (infliximab); SB5 biosimilar candidate referencing Humira (adalimumab); SB9 (MK-1293) biosimilar candidate referencing Lantus (insulin glargine); SB3 biosimilar candidate referencing Herceptin (trastuzumab); SB8 biosimilar candidate referencing Avastin (bevacizumab)

http://www.pharmabiz.com/NewsDetails.aspx?aid=97439&sid=2

Republicado por:RM Consult